NEW YORK (GenomeWeb) — Janssen Diagnostics said last week that it is now offering research services on its Cellsearch system for circulating tumor cell preparation in conjunction with Asuragen's SuraSeq next-generation sequencing cancer panels.
NEW YORK (GenomeWeb News) – Arno Therapeutics today announced an agreement with Johnson & Johnson's Veridex to develop a companion diagnostic for identifying patients who may benefit from anti-progestin cancer therapeutics.
At a meeting hosted by the Centers for Medicare & Medicaid Services this week to determine payment levels for genetic tests placed in the clinical laboratory fee schedule, lab industry professionals remained at loggerheads with pathologists who maintained that the physician f
Veridex of Raritan, NJ, has received US Patent No. 8,183,353, "Breast cancer prognostics." A method is claimed for assessing the likelihood of a recurrence or metastasis of breast cancer in a patient diagnosed with or treated for breast cancer.
NEW YORK (GenomeWeb News) – Veridex and Novartis are partnering to "encourage and facilitate" research into circulating tumor cells as potential biomarkers in metastatic prostate cancer, Veridex announced today.
Skyline Diagnostics' AMLprofiler leukemia test recently became the fourth Affy-based test to hit the market. Some of the company's other diagnostic partners, however, have changed their development strategies since the "Powered by Affymetrix" program was launched.